Cozaar®XQ® Tablet 5mg100mg Singapoo - Kiingereza - HSA (Health Sciences Authority)

cozaar®xq® tablet 5mg100mg

organon singapore pte. ltd. - amlodipine camsylate 7.84mg eqv to amlodipine; losartan 91.52mg eqv to losartan potassium - tablet, film coated - 5mg - amlodipine camsylate 7.84mg eqv to amlodipine 5mg; losartan 91.52mg eqv to losartan potassium 100.00mg

Cozaar®XQ® Tablet 5mg50mg Singapoo - Kiingereza - HSA (Health Sciences Authority)

cozaar®xq® tablet 5mg50mg

organon singapore pte. ltd. - amlodipine camsylate 7.84mg eqv to amlodipine; losartan 45.76mg eqv to losartan potassium - tablet, film coated - 5mg - amlodipine camsylate 7.84mg eqv to amlodipine 5mg; losartan 45.76mg eqv to losartan potassium 50.00mg

Cubicin Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

cubicin

merck sharp & dohme b.v. - daptomycin - gram-positive bacterial infections; bacteremia; soft tissue infections; endocarditis, bacterial - antibacterials for systemic use, - cubicin is indicated for the treatment of the following infections.adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cssti).adult patients with right-sided infective endocarditis (rie) due to staphylococcus aureus.it is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.adult and paediatric (1 to 17 years of age) patients with staphylococcus aureus bacteraemia (sab). in adults, use in bacteraemia should be associated with rie or with cssti, while in paediatric patients, use in bacteraemia should be associated with cssti.daptomycin is active against gram positive bacteria only. in mixed infections where gram negative and/or certain types of anaerobic bacteria are suspected, cubicin should be co-administered with appropriate antibacterial agent(s). consideration should be given to official guidance on the appropriate use of antibacterial agents.

Janumet Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

janumet

merck sharp & dohme b.v. - sitagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for patients with type 2 diabetes mellitus:janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.janumet is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.janumet is indicated as triple combination therapy with a ppar  agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a ppar  agonist.janumet is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.

Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

efavirenz/emtricitabine/tenofovir disoproxil zentiva

zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir

LEDAGA Israeli - Kiingereza - Ministry of Health

ledaga

rafa laboratories ltd - chlormethine as hydrochloride - gel - chlormethine as hydrochloride 160 mcg/g - chlormethine - topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin-directed therapy

Supemtek Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

supemtek

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influenza, human - vaccines - supemtek is indicated for active immunization for the prevention of influenza disease in adults.supemtek should be used in accordance with official recommendations.

Apheresis unit Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

apheresis unit

aa-med pty ltd - 16405 - apheresis unit - cell separator for the automated processing of blood components, including sterile, single use application kits. this device is not intended for direct patient connection.

Haematological concentrate system kit, platelet concentration Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

haematological concentrate system kit, platelet concentration

emergo asia pacific pty ltd t/a emergo australia - 90000 - obsolete - haematological concentrate system kit, platelet concentration - these kits with necessary components are used for the separation of bone marrow/whole blood mixture using magellan platelt separator instrument which is intended for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of a mixture of blood and bone marrow and for the preparation of cell concentrate from bone marrow.